Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2013

01-03-2013 | Bone and Soft Tissue Sarcomas

Factors Affecting Prognosis of Patients with Giant Cell Tumors of the Mobile Spine: Retrospective Analysis of 102 Patients in a Single Center

Authors: Wei Xu, MD, Xiang Li, MD, Wending Huang, MD, Yu Wang, MD, Shuai Han, MD, Su Chen, MD, Leqin Xu, MD, Xinghai Yang, MD, Tielong Liu, MD, Jianru Xiao, MD

Published in: Annals of Surgical Oncology | Issue 3/2013

Login to get access

Abstract

Background

Giant cell tumor (GCT) of the mobile spine is a benign tumor, but it can be potentially aggressive. There is not much published information on GCT of the mobile spine as a result of rarity of the disease, and there are controversies over prognostic factors of the condition.

Methods

A retrospective analysis of GCT of the mobile spine was performed by survival analysis. Recurrence-free survival (RFS) was defined as the interval between the date of surgery and the date of recurrence. The postoperative RFS rate was estimated by the Kaplan–Meier method. Factors with P values of ≤0.1 were subjected to multivariate analysis for RFS by proportional hazard analysis. P values of ≤0.5 were considered statistically significant.

Results

A total of 102 patients with GCT of the mobile spine were included in the study. The mean follow-up period was 39.9 (median 26.0, range 2–153) months. Thirty-eight patients developed recurrence. The univariate and multivariate analysis suggested that age less than 40 years, total spondylectomy either by en bloc or piecemeal method, and administration of bisphosphonate were independent favorable prognostic factors. Subgroup analysis by excluding patients before the year 2000 further confirmed our findings.

Conclusions

The removal of the entire osseous compartment either by en bloc or piecemeal method in combination with the long-term use of bisphosphonate could significantly reduce the recurrence rate of GCT of the mobile spine. Age less than 40 years is a favorable prognostic factor for GCT in the mobile spine.
Appendix
Available only for authorised users
Literature
1.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106–14.PubMed
2.
Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop. 2006;30:484–9.PubMedCrossRef
3.
Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am. 1970;52:619–64.PubMed
4.
Larsson SE, Lorentzon R, Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish cancer registry for the years 1958 through 1968. J Bone Joint Surg Am. 1975;57:167–73.PubMed
5.
Sanjay BK, Sim FH, Unni KK, McLeod RA, Klassen RA. Giant-cell tumours of the spine. J Bone Joint Surg Br. 1993;75:148–54.PubMed
6.
Gamberi G, Benassi MS, Ragazzini P, et al. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone. Ann Oncol. 2004;15:498–503.PubMedCrossRef
7.
Dahlin DC. Caldwell Lecture. Giant cell tumor of bone: highlights of 407 cases. AJR Am J Roentgenol. 1985;144:955–60.PubMed
8.
Eckardt JJ, Grogan TJ. Giant cell tumor of bone. Clin Orthop Relat Res. 1986;(204):45–58.PubMed
9.
Boriani S, Bandiera S, Casadei R, et al. Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976). 2012;37:E37–45.CrossRef
10.
Savini R, Gherlinzoni F, Morandi M, Neff JR, Picci P. Surgical treatment of giant-cell tumor of the spine. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am. 1983;65:1283–9.PubMed
11.
Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN. A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine (Phila Pa 1976). 1997;22:1773–82.CrossRef
12.
Martin C, McCarthy EF. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J. 2010;30:69–75.PubMed
13.
Junming M, Cheng Y, Dong C, et al. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976). 2008;33:280–8.CrossRef
14.
Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case–control study. Bone. 2008;42:68–73.PubMedCrossRef
15.
Frankel HL, Hancock DO, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia. 1969;7:179–92.PubMedCrossRef
16.
Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer. 1980;46:1641–9.PubMedCrossRef
17.
Boriani S, Weinstein JN, Biagini R. Primary bone tumors of the spine. Terminology and surgical staging. Spine (Phila Pa 1976). 1997;22:1036–44.CrossRef
18.
Chan P, Boriani S, Fourney DR, et al. An assessment of the reliability of the Enneking and Weinstein–Boriani–Biagini classifications for staging of primary spinal tumors by the spine oncology study group. Spine (Phila Pa 1976). 2009;34:384–91.CrossRef
19.
Boriani S, Biagini R, De Iure F, et al. En bloc resections of bone tumors of the thoracolumbar spine. A preliminary report on 29 patients. Spine (Phila Pa 1976). 1996;21:1927–31.CrossRef
20.
Tomita K, Kawahara N, Baba H, Tsuchiya H, Fujita T, Toribatake Y. Total en bloc spondylectomy. A new surgical technique for primary malignant vertebral tumors. Spine (Phila Pa 1976). 1997;22:324–33.CrossRef
21.
Song S, Hong JC, McDonnell SE, et al. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012;19:2471–6.PubMedCrossRef
22.
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. 2003;97:2520–9.PubMedCrossRef
23.
24.
Guo C, Yan Z, Zhang J, et al. Modified total en bloc spondylectomy in thoracic vertebra tumour. Eur Spine J. 2011;20:655–60.PubMedCrossRef
25.
Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004;75:71–7.PubMedCrossRef
26.
Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res. 2004;(426):103–9.PubMedCrossRef
27.
Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer. 2010;10:462.PubMedCrossRef
28.
Zhang W, Zhang Y, Li P, et al. Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. Spine (Phila Pa 1976). 2011;36:E1166–72.CrossRef
29.
Otto S, Sotlar K, Ehrenfeld M, Pautke C. Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: a case report. J Med Case Rep. 2011;5:477.PubMedCrossRef
30.
Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature. Cancer. 1979;44:1393–402.PubMedCrossRef
31.
Gong L, Liu W, Sun X, et al. Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 2012;460:327–34.PubMedCrossRef
32.
Ozkan E, Gupta S. Embolization of spinal tumors: vascular anatomy, indications, and technique. Tech Vasc Interv Radiol. 2011;14:129–40.PubMedCrossRef
33.
Vetter SC, Strecker EP, Ackermann LW, Harms J. Preoperative embolization of cervical spine tumors. Cardiovasc Interv Radiol. 1997;20:343–7.PubMedCrossRef
34.
Zhen W, Yaotian H, Songjian L, Ge L, Qingliang W. Giant-cell tumour of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br. 2004;86:212–6.PubMedCrossRef
35.
Durr HR, Maier M, Jansson V, Baur A, Refior HJ. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol. 1999;25:610–8.PubMedCrossRef
36.
Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res. 1999;(359):176–88.PubMedCrossRef
37.
Wei F, Liu X, Liu Z, et al. Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine (Phila Pa 1976). 2010;35:E1418–22.
38.
Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol. 1993;119:301–3.PubMedCrossRef
39.
Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275–80.PubMedCrossRef
Metadata
Title
Factors Affecting Prognosis of Patients with Giant Cell Tumors of the Mobile Spine: Retrospective Analysis of 102 Patients in a Single Center
Authors
Wei Xu, MD
Xiang Li, MD
Wending Huang, MD
Yu Wang, MD
Shuai Han, MD
Su Chen, MD
Leqin Xu, MD
Xinghai Yang, MD
Tielong Liu, MD
Jianru Xiao, MD
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2707-6

Other articles of this Issue 3/2013

Annals of Surgical Oncology 3/2013 Go to the issue

Breast Oncology

Utilization of Mastectomy and Reconstruction in the Outpatient Setting

Gynecologic Oncology

Development of Criteria for Ovarian Preservation in Cervical Cancer Patients Treated with Radical Surgery With or Without Neoadjuvant Chemotherapy: A Multicenter Retrospective Study and Meta-analysis

Urologic Oncology

Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy

Breast Oncology

Lifestyle Risk Factors Associated with Arm Swelling Among Women with Breast Cancer

Colorectal Cancer

The Effect of Intraoperative Rectal Washout on Local Recurrence after Rectal Cancer Surgery: A Meta-Analysis

Gastrointestinal Oncology

Significant Variation of Resected Meso-esophageal Tissue Volume in Two-Stage Subtotal Esophagectomy Specimens: A Retrospective Morphometric Study